Hsbc Holdings PLC Makes New Investment in Indivior PLC (NASDAQ:INDV)

Hsbc Holdings PLC bought a new stake in shares of Indivior PLC (NASDAQ:INDV) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 42,955 shares of the company’s stock, valued at approximately $649,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Scopia Capital Management LP purchased a new stake in Indivior in the 3rd quarter worth approximately $191,743,000. Vanguard Group Inc. boosted its position in Indivior by 1.6% during the third quarter. Vanguard Group Inc. now owns 5,846,354 shares of the company’s stock valued at $134,875,000 after purchasing an additional 90,673 shares during the last quarter. FMR LLC grew its stake in Indivior by 53.5% in the third quarter. FMR LLC now owns 5,498,087 shares of the company’s stock valued at $119,339,000 after purchasing an additional 1,915,980 shares in the last quarter. Norges Bank purchased a new position in Indivior in the fourth quarter valued at about $36,011,000. Finally, Liontrust Investment Partners LLP purchased a new stake in shares of Indivior during the 3rd quarter worth about $43,340,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum began coverage on Indivior in a research note on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price target for the company.

Indivior Stock Up 0.1 %

Shares of INDV stock traded up $0.02 on Friday, hitting $17.95. The company’s stock had a trading volume of 96,887 shares, compared to its average volume of 125,006. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of 1,795.00 and a beta of 0.63. Indivior PLC has a fifty-two week low of $14.38 and a fifty-two week high of $26.50. The firm’s fifty day moving average price is $20.38 and its 200-day moving average price is $18.23. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.92 and a quick ratio of 0.74.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.15. Indivior had a return on equity of 842.72% and a net margin of 0.44%. The company had revenue of $293.00 million during the quarter, compared to analysts’ expectations of $260.00 million. Research analysts anticipate that Indivior PLC will post 2 EPS for the current year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.